Objectives: This study sought to investigate the evolving pattern over time of on-clopidogrel platelet reactivity (PR) and its relationship with genotype and clinical outcomes after percutaneous coronary intervention. Background: Whether on-clopidogrel PR and role of genotype differ over time is unknown. Methods: On-clopidogrel PR before percutaneous coronary intervention, and 1 and 6 months thereafter via VerifyNow P2Y12 (Accumetrics Inc., San Diego, California), CYP2C19 (*)2, (*)17, CYP3A5 (*)3, and ABCB1 polymorphisms were evaluated in 300 patients. Death, stroke, myocardial infarction, and bleedings were assessed up to 1 year. Results: On-clopidogrel PR varied significantly over time, being higher at baseline than at 1 and 6 months after. From baseline to 1 month, 83 of 300 patients varied their response status. This was mainly due to baseline poor responders becoming full responders (75 of 83). Genotype justifies roughly 18% of this trend. CYP2C19 (*)2 and (*)17 influence on PR was consistent over time, whereas that of ABCB1 appeared of greater impact at baseline. On-clopidogrel PR at 1 month independently best predicts ischemic and bleeding events. We found a therapeutic window (86 to 238 P2Y12 reactivity units) with a lower incidence of both ischemic and bleeding complications. A risk score was created by combining genotype (ABCB1 and CYP2C19 (*)2), baseline PR, and creatinine clearance to predict 1-month poor responsiveness and 1-year poor prognosis. Conclusions: In patients at steady state for clopidogrel undergoing percutaneous coronary intervention, PR decreases from baseline to 1 month. Genotype influences ≈18% of this trend. On-clopidogrel PR at 1 month is the strongest predictor of adverse outcomes, and this can be predicted by combining genotype to baseline phenotype and clinical variables. © 2011 American College of Cardiology Foundation.

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship with gene polymorphisms and clinical outcome

CAMPO, Gianluca Calogero;FERRARESI, Paolo;LUNGHI, Barbara;TEBALDI, Matteo;MARCHESINI, Jlenia;BERNARDI, Francesco;FERRARI, Roberto;VALGIMIGLI, Marco
2011

Abstract

Objectives: This study sought to investigate the evolving pattern over time of on-clopidogrel platelet reactivity (PR) and its relationship with genotype and clinical outcomes after percutaneous coronary intervention. Background: Whether on-clopidogrel PR and role of genotype differ over time is unknown. Methods: On-clopidogrel PR before percutaneous coronary intervention, and 1 and 6 months thereafter via VerifyNow P2Y12 (Accumetrics Inc., San Diego, California), CYP2C19 (*)2, (*)17, CYP3A5 (*)3, and ABCB1 polymorphisms were evaluated in 300 patients. Death, stroke, myocardial infarction, and bleedings were assessed up to 1 year. Results: On-clopidogrel PR varied significantly over time, being higher at baseline than at 1 and 6 months after. From baseline to 1 month, 83 of 300 patients varied their response status. This was mainly due to baseline poor responders becoming full responders (75 of 83). Genotype justifies roughly 18% of this trend. CYP2C19 (*)2 and (*)17 influence on PR was consistent over time, whereas that of ABCB1 appeared of greater impact at baseline. On-clopidogrel PR at 1 month independently best predicts ischemic and bleeding events. We found a therapeutic window (86 to 238 P2Y12 reactivity units) with a lower incidence of both ischemic and bleeding complications. A risk score was created by combining genotype (ABCB1 and CYP2C19 (*)2), baseline PR, and creatinine clearance to predict 1-month poor responsiveness and 1-year poor prognosis. Conclusions: In patients at steady state for clopidogrel undergoing percutaneous coronary intervention, PR decreases from baseline to 1 month. Genotype influences ≈18% of this trend. On-clopidogrel PR at 1 month is the strongest predictor of adverse outcomes, and this can be predicted by combining genotype to baseline phenotype and clinical variables. © 2011 American College of Cardiology Foundation.
2011
Campo, Gianluca Calogero; Parrinello, G.; Ferraresi, Paolo; Lunghi, Barbara; Tebaldi, Matteo; Miccoli, M.; Marchesini, Jlenia; Bernardi, Francesco; Ferrari, Roberto; Valgimigli, Marco
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/1482118
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 313
  • ???jsp.display-item.citation.isi??? 291
social impact